Por: Portland Press Herald World December 01, 2023
AbbVie will pay around $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales. But company leaders cautioned Thursday that a return on the deal they announced for drug developer ImmunoGen will take time to develop. The company said it will pay $31.26 in cash for each ImmunoGen share. That amounts to a 95% premium on the stock’s closing closing price... + full article
RTTNews USA Health September 29, 2023
AbbVie () announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more... + más
How a Drug Company Made $114 Billion by Gaming the U.S. Patent System | The New York Times
AbbVie Posts an Earnings Beat but Forecast Misses as Competition Intensifies | MarketWatch
ESPN USA Sports May 27, 2023
A complete list of NBA champions:2022 -- over 2021 -- over 2020 -- over 2019 -- over Golden State Warriors2018 -- Golden State Warriors over 2017 -- Golden State Warriors over Cleveland Cavaliers2016 -- over Golden State Warriors2015 -- Golden State Warriors over Cleveland... + más
NFL Playoff Scenarios | ABC News
Le Krewe du Roi celebrates the state at 58th annual Mardi Gras Ball | The Advocate
New York Post USA Sports April 17, 2023
The Post’s Larry Brooks, Mollie Walker and Ethan Sears give their predictions for the 2023 NHL playoffs: Larry Brooks First round Eastern Conference Bruins over Panthers in 5 Maple Leafs over Lightning in 6 Hurricanes over Islanders in 6 Rangers over Devils in 7 Western... + más
5 Teams with Best Chance to End Boston Bruins Stanley Cup Dreams | Bleacher Report
Elvis Presley’s stepbrother says he spoke of God’s forgiveness before his death: 'In touch with the Lord' | Fox News
MarketWatch USA Business February 09, 2023
International sales of Humira fell 26.5% from last year as the company lost patent protection in Europe and . However, revenue for the drug that treats Crohn’s disease grew 4.6% globally in the quarter to $5.58 billion, which was slightly above analysts’ estimates. said... + más
Cigna’s PBM Express Scripts Latest To Put Less Pricey Biosimilars Of Abbvie’s Humira On Preferred Drug List | Forbes
The New York Times USA Business January 28, 2023
In 2016, a blockbuster drug called Humira was poised to become a lot less valuable.The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug,... + más
Will More Women Patent Attorneys Lead To More Women Inventors? | Forbes
Samsung Beats IBM, Apple, Intel, Google For 2022 Patent Crown; 56% Of U.S. Patents Go To Foreign Firms | Forbes
MarketWatch USA Business January 22, 2023
A few weeks later, in December, the biotechnology company BeiGene stole the show at the American Society of Hematology’s big annual meeting in New Orleans. BeiGene showing its Btk inhibitor pill, Brukinsa, beating Imbruvica on efficacy and safety in a trial of CLL patients. ... + más
Shaikin: Baseball embracing the 'flukes' and plenty of added revenue this postseason | Los Angeles Times
Watch the wreck of the Brookhill ferry return to the waters of the Mississippi River | The Advocate
Forbes USA Tech December 05, 2022
Cigna’s pharmacy benefit manager Express Scripts will put “multiple biosimilar versions of Abbvie’s ... [+] expensive rheumatoid arthritis drug Humira in the “same position as the brand” on the PBM’s as a formulary in 2023. AbbVie's signature drug Humira is... + más
Cigna received millions of Medicare dollars based on invalid diagnoses, lawsuit claims | ABC News
How To Get Away With Corporate Murder: Unbundling And Disrupting Pharmacy Benefit Managers (Part 2) | Forbes
About iurex | Privacy Policy | Disclaimer |